Genetics of Anxiety Disorders - Status Quo and Quo Vadis

Author(s): Katharina Domschke, Jurgen Deckert.

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 35 , 2012

Become EABM
Become Reviewer

Abstract:

Clinical genetic studies propose a strong genetic contribution to the pathogenesis of anxiety disorders with a heritability of about 30-67%. The present review will give an overview of linkage studies, association studies and genome-wide association studies (GWAS) yielding support for some candidate genes. Additionally, first evidence for gene-environment interactions between candidate genes of anxiety disorders and stressful life events will be reported. On a systems level, neural activation correlates of anxiety-relevant emotional processing and neurophysiological measures such as peripheral sympathetic activity or the startle reflex have been shown to be potentially driven by vulnerability genes of anxiety disorders. Promising current approaches to further dissect the genetic underpinnings of anxiety disorders such as next generation sequencing, epigenetic analyses and pharmaco-/ psychotherapy-genetics will be presented. Genetic research in anxiety disorders will be discussed with respect to its potential benefit for future efforts to develop innovative and individually tailored therapeutic approaches for patients with anxiety disorders.

Keywords: Linkage, association, genome-wide association, gene-environment interaction, imaging genetics, epigenetics, pharmacogenetics

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 18
ISSUE: 35
Year: 2012
Page: [5691 - 5698]
Pages: 8
DOI: 10.2174/138161212803530781
Price: $58

Article Metrics

PDF: 14